Summary & Overview
HCPCS G9827: HER2-Targeted Therapies Not Administered During Initial Treatment
HCPCS Level II code G9827 signals that HER2-targeted therapies were not administered during a patient’s initial course of treatment. Nationally, this code matters for tracking adherence to recommended oncology treatment pathways, documenting deviations from expected care sequences, and supporting administrative and quality reporting in oncology practices and payer systems. It provides a standardized way to capture cases where HER2-directed agents are initiated later or withheld, which can influence treatment planning, quality measurement, and claims adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical and administrative purpose of G9827, typical sites of service where it appears, and how the code interacts with oncology care delivery. The publication outlines common billing and reporting considerations, summarizes benchmark uses for payers, and flags areas where payers and providers commonly seek clarification.
The content is intended for a national audience of providers, coders, and payer policy staff who need a concise reference on what G9827 represents, why it is captured, and how it fits into broader oncology billing and quality measurement workflows. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code G9827 denotes HER2-targeted therapies not administered during the initial course of treatment. The code is used to indicate that a patient with HER2-positive cancer did not receive HER2-directed agents as part of their initial systemic treatment plan.
Service Type: Systemic oncology therapy management / Administration tracking
Typical Site of Service: Outpatient oncology clinics, infusion centers, or other non-inpatient settings where systemic cancer therapy decisions and administrations are documented
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a woman diagnosed with HER2-positive invasive breast cancer who did not receive HER2-targeted therapy (for example, trastuzumab or pertuzumab) during the initial course of treatment. This scenario commonly occurs when a patient presents with comorbid conditions, active infection, cardiac dysfunction, or concurrent pregnancy that contraindicates immediate HER2-targeted infusion, or when initial surgery and pathologic staging occur before medical oncology consultation. The clinical workflow involves: initial diagnosis by surgical oncology or outpatient breast clinic; pathology confirmation of HER2 status with immunohistochemistry and/or FISH; multidisciplinary tumor board discussion; deferral of HER2-targeted systemic therapy at initial treatment; subsequent medical oncology evaluation and clearance (including cardiac assessment such as echocardiogram or MUGA); scheduling and administration of HER2-targeted therapy in an infusion center or outpatient oncology clinic; and documentation for billing that HER2-targeted therapies were not administered during the initial course of treatment, supporting use of the G9827 HCPCS Level II code when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work or complexity of pre-infusion evaluation or documentation is substantially greater than usual for administering deferred HER2 therapy |